Multiple regenerative therapies (e.g., mesenchymal stromal cells, platelet derived products, autologous conditioned serum or protein solution, amnion, urinary bladder matrix, alpha-2 macroglobulin from various tissue sources including bone marrow, blood, adipose or bladder) are marketed to veterinarians. However, mechanism of action, comparative biological activity, and consistent product formulation to guide informed decisions in treatment selection and disease application are not available in many instances. The role of the innate immune system in inducing and perpetuating chronic low-grade inflammation in multiple disease states (i.e., osteoarthritis) is increasingly recognized and therefore immunomodulation through use of regenerative therapies (e.g., secreted exosomes, cell-cell interactions etc.) represents a therapeutic strategy for further investigation.
With this article collection, our goal is to promote One Health strategies and transdisciplinary approaches to improve the understanding of the immunomodulatory role of regenerative therapies in various clinical applications in veterinary medicine or to enhance animal regeneration techniques from human medical research. We aim to create an article collection to share innovative perspectives from specialists across research backgrounds (e.g., immunology, engineering, medicine) to begin to address pressing questions in the field of regenerative therapies.
We will welcome Original Research Articles, Brief Research Reports, Method Articles, Perspectives, Opinion Articles or Mini Reviews which present or discuss research in veterinary regenerative medicine specifically aiming to understand the interaction with the immune system, which may lead to improved understanding of or optimized treatment strategies towards multiple applications. We would invite a broad scope of approaches, including tissue engineering and stromal cell-based therapies if associated with veterinary regenerative medicine.
Multiple regenerative therapies (e.g., mesenchymal stromal cells, platelet derived products, autologous conditioned serum or protein solution, amnion, urinary bladder matrix, alpha-2 macroglobulin from various tissue sources including bone marrow, blood, adipose or bladder) are marketed to veterinarians. However, mechanism of action, comparative biological activity, and consistent product formulation to guide informed decisions in treatment selection and disease application are not available in many instances. The role of the innate immune system in inducing and perpetuating chronic low-grade inflammation in multiple disease states (i.e., osteoarthritis) is increasingly recognized and therefore immunomodulation through use of regenerative therapies (e.g., secreted exosomes, cell-cell interactions etc.) represents a therapeutic strategy for further investigation.
With this article collection, our goal is to promote One Health strategies and transdisciplinary approaches to improve the understanding of the immunomodulatory role of regenerative therapies in various clinical applications in veterinary medicine or to enhance animal regeneration techniques from human medical research. We aim to create an article collection to share innovative perspectives from specialists across research backgrounds (e.g., immunology, engineering, medicine) to begin to address pressing questions in the field of regenerative therapies.
We will welcome Original Research Articles, Brief Research Reports, Method Articles, Perspectives, Opinion Articles or Mini Reviews which present or discuss research in veterinary regenerative medicine specifically aiming to understand the interaction with the immune system, which may lead to improved understanding of or optimized treatment strategies towards multiple applications. We would invite a broad scope of approaches, including tissue engineering and stromal cell-based therapies if associated with veterinary regenerative medicine.
